Zidesamtinib achieves 93% response rate in ROS1-positive lung cancer
Reported byMedicalXpress ↗·Sourced by Goodlede
A global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer who had not previously received a tyrosine kinase inhibitor, with a 93% response rate, presented at the International Association for the Study of Lung Cancer 2026 World Conference.
Early-phase trial (phase 1/2) in a rare cancer subtype; broader efficacy and safety data will require larger studies.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at MedicalXpress
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
David vs Goliath
Formerly incarcerated women won a lawsuit requiring Texas to air-condition all prisons by 2029
The 19th · Verified
Arts
Archaeologists risked their lives to save 30,000 treasures from ISIS destruction
Good News Network · Verified
Animals
Terns, Skimmers Thrive on Recently Conserved Island in North Carolina
Audubon · Verified